Acelyrin's IPO is an 'N of 1', industry insiders say, as 50+ biotechs are still waiting for their moment on the markets
California drug developer Acelyrin landed on the Nasdaq Friday morning in one of the largest biotech debuts since 2021, at $540 million, but the ringing of the bell is not likely to herald a rush-to-market like the pandemic’s first year.
Acelyrin’s stock $SLRN jumped about 28% in trading on Friday.
Acelyrin’s upsized initial public offering is still a rarity in a capital market hampered by high-interest rates, a banking crisis, the war in Ukraine and other macro challenges, according to industry executives and insiders who spoke with Endpoints News.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.